c-Met receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Ankylosing spondylitis was distinguished from rheumatoid arthritis by Galen as early as the 2nd century AD. Skeletal evidence of the disease (ossification of joints and entheses primarily of the axial skeleton, known as "bamboo spine") was thought to be found in the skeletal remains of a 5000-year-old Egyptian mummy. However, a subsequent report found that this was not the case. The anatomist and surgeon Realdo Colombo described what could have been the disease in 1559, and the first account of pathologic changes to a skeleton possibly associated with AS was published in 1691 by Bernard Connor. In 1818, Benjamin Brodie became the first physician to document a person believed to have active AS who also had accompanying iritis. In 1858, David Tucker published a small booklet which clearly described the case of Leonard Trask, who had severe spinal deformity subsequent to AS. In 1833, Trask fell from a horse, exacerbating the condition and resulting in severe deformity. Tucker reported:
The production was noted (by Nehad Selaiha of the weekly Al-Ahram) not only for its unexpected change of plot at the very end but also for its chorus of one hundred who alternated their speech between Arabic and English. The translation used was that of George Theodoridis. US Latina playwright Caridad Svich's 2009 play Wreckage, which premiered at Crowded Fire Theatre in San Francisco, tells the story of Medea from the sons' point of view, in the afterlife. Paperstrangers Performance Group toured a critically acclaimed production of Medea directed by Michael Burke to U.S. Fringe Festivals in 2009 and 2010. Bart Lee's interpretation of Medea, renamed Medea, My Dear, was performed in Surrey and later toured the south of England from 2010 to 2011. Luis Alfaro's re-imagining of Medea, Mojada, world premiered at Victory Gardens Theater in 2013. Theatre Lab's production, by Greek director Anastasia Revi, opened at The Riverside Studios, London, on 5 March 2014. The Hungry Woman: A Mexican Medea by Cherríe Moraga takes elements of Medea and of other works. 14 July – 4 September 2014 London Royal National Theatre staging of Euripides in a new version by Ben Power, starring Helen McCrory as Medea, directed by Carrie Cracknell, music by Will Gregory and Alison Goldfrapp. 25 September – 14 November 2015 London Almeida Theatre a new adaptation by Rachel Cusk, starring Kate Fleetwood as Medea, directed by Rupert Goold. 17 February – 6 March 2016 in Austin at the Long Center for the Performing Arts starring Franchelle Stewart Dorn as Medea and directed by Ann Ciccolella.
Blue Shift was announced in the second quarter of 2000 as part of an upcoming Dreamcast port of Half-Life. While the port was developed by Captivation Digital Laboratories, Blue Shift was developed by Gearbox Software, who also developed the first Half-Life expansion, Opposing Force. The game had the working title Half-Life: Guard Duty; publisher Sierra Entertainment announced the name Blue Shift on August 30, 2000. As with Opposing Force, the title has a double meaning, referring to both the blue shift light phenomenon and the name of Barney's shift. The Dreamcast port would include higher detail models and textures that were double the polygon count of Valve's original Half-Life models. At the European Computer Trade Show in September 2000, information about Blue Shift's story and development direction was revealed, along with a release date of November 1, 2000, for the Dreamcast version of Half-Life. The port was delayed by Sierra to ensure the "high expectations of consumers" were met, anticipating release by the end of the year. On March 29, 2001, Sierra announced that Blue Shift would also be released for Windows as a standalone game that would not require the original Half-Life to run. The new models developed for the Dreamcast version would also be included in the PC version as the Half-Life High Definition pack, and could be applied to Half-Life and Opposing Force. At the E3 2001, Gearbox announced that Blue Shift was complete and exhibited a playable version. It was released on June 12, 2001, in North America, and on June 15 in Europe.
. You can make sense of this by considering the ideal gas law p = ρRT (which is valid if the Reynolds number is large enough that viscous friction becomes unimportant). Then, even for an adiabatic, chemically-homogenous fluid, the density can vary when the pressure changes, e.g. with Bernoulli. For inviscid fluids, the viscosity tensor τ is zero. Thus for an inviscid, barotropic fluid with conservative body forces, the vorticity equation simplifies to
Sources: en.wikipedia.org
Dihydrowogonin is a natural product, which as a flavonoid belongs to the flavanone subclass. It has a flavan backbone with a hydroxyl and methoxy functional groups. It possesses some antioxidant, anti-inflammatory, and neuroprotective properties. Dihydrowogonin has been identified as a major constituent in the methanol extract of the species, Prunus avium (wild cherry), mostly in the bark. Dihydrowogonin appears to exhibit antimicrobial and antibiofilm behaviour, particularly against the Gram-positive bacteria like Staphylococcus aureus. In addition, it can interact with glutathione transferases in white-rot fungi; thus, this suggests a role in the detoxification processes during wood degradation. It has been studied for potential applications in pharmacology, particularly as an antimicrobial and antioxidant agent, and in neuroprotective therapies.
On February 12, 2015, FIFA renewed the United States and Canadian broadcasting rights contracts for Fox Sports (U.S. English), Telemundo Deportes (U.S. Spanish), and Bell Media (Canada) to cover the 2026 World Cup, without accepting any other bids. A report in The New York Times asserted that this extension was intended as compensation for the rescheduling of the 2022 World Cup to November–December rather than its traditional June–July scheduling, as it created considerable conflicts with major professional sports leagues that were normally in their offseasons during the World Cup.
== Biochemistry at Yale == In 1945, after Max Bergmann's death, Fruton joined the Yale University Department of Physiological Chemistry (part of the medical school) —headed then by C. N. Hugh Long—where he taught biological chemistry to medical students. Fruton joined a growing science faculty, which included the editor of the Journal of Biological Chemistry, Rudolph Anderson; biochemist Edward Tatum also came to Yale at the same time. In addition to research and teaching at Yale, in 1948 Fruton visited the laboratories of several eminent biochemists: Kaj Linderstrøm-Lang's chemistry department at the Carlsberg Laboratory; Hugo Theorell's lab in Stockholm; and Alexander Todd's lab at Cambridge University. At the end of his five-year appointment as assistant professor, Fruton was promoted to full professor received a joint appointment in the chemistry department—at the time, the only Jewish full professor in the medical school. By 1952, he was elected to the National Academy of Sciences, and that year he also became chairman of the Department of Physiological Chemistry (which was renamed Biochemistry, reflecting the shift in research focus from medical to general biological problems). He was elected to the American Academy of Arts and Sciences in 1953. Most of Fruton's early research at Yale was funded by a grant from the Rockefeller Foundation; Warren Weaver was making enzymology one of the Foundation's research focuses. Fruton headed a growing lab that included doctoral students, postdoctoral researchers, and technical assistants.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.